Private company

Constellation Pharmaceuticals (United States)

Logo: constellationpharma.com³

Constellation Pharmaceuticals (United States) is an American pharmaceutical preparations company based in Cambridge.¹ It was founded in 2008.¹

Last updated Oct 20, 2026.

Overview

2008Founded¹

IndustryPharmaceutical Preparations¹
HeadquartersCambridge¹
Websitewww.constellationpharma.com
Incorporated inDE⁴
Business address215 First Street, Suite 200, Cambridge, Ma 02142⁴
Filer categoryLarge accelerated filer⁴

See how the biggest companies compare on our leaderboards

Image: constellationpharma.com³

What it owns

What Constellation Pharmaceuticals (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, before depreciation	$8.3M⁵ Dec 31, 2020	$7.8M⁵ Dec 31, 2019	+7.0%
Accumulated depreciation	$6.8M⁵ Dec 31, 2020	$6.8M⁵ Dec 31, 2019	+0.3%
Property and equipment, net	$1.5M⁵ Dec 31, 2020	$971.0K⁵ Dec 31, 2019	+54.2%
Operating-lease assets (leased space)	$3.5M⁵ Dec 31, 2020	$10.7M⁵ Dec 31, 2019	−67.0%

Real estate and locations

Item	Latest	A year before	Change
Area of land	47,546 sq ft⁵ Dec 31, 2020	36,309 sq ft⁶ Dec 31, 2019	+30.9%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$163.7M⁵ Dec 31, 2020	$334.3M⁵ Dec 31, 2019	−51.0%
Marketable securities, current	$257.8M⁵ Dec 31, 2020	$49.6M⁵ Dec 31, 2019	+419.6%
Debt securities available for sale	$257.8M⁵ Dec 31, 2020	$49.6M⁵ Dec 31, 2019	+419.6%

Leadership

Who has led Constellation Pharmaceuticals (United States), and when. Pick a name to see everywhere that person has worked.

2010201520202025

Chief executive officerJigar Raythatha Jul 18, 2018 to Feb 18, 2020⁷
PresidentJigar Raythatha Jul 18, 2018 to Feb 18, 2020⁷
Chief financial officerEmma Reeve Jul 18, 2018 to Jul 19, 2021⁸

Board members and other officers (16)

Chief Medical OfficerJeffrey Humphrey Jul 8, 2020 to Jul 19, 2021⁹
Chief Medical OfficerAdrian Senderowicz Jul 18, 2018 to May 13, 2020¹⁰
OfficerKaren Valentine Jul 18, 2018 to Jul 19, 2021¹¹
OfficerJigar Raythatha Jul 20, 2018 to Jul 19, 2021¹²
Chief Scientific OfficerPatrick Trojer Nov 30, 2018 to Jul 19, 2021¹³
Board memberScott Braunstein Feb 20, 2019 to Jul 19, 2021¹⁴
Board memberAnthony B. Evnin Jul 18, 2018 to Dec 16, 2019¹⁵
Board memberBihua Chen Jul 18, 2018 to Jul 20, 2018¹⁶
Board memberJames E. Audia Jul 18, 2018 to Jul 19, 2021¹⁷
Board memberJigar Raythatha Jul 18, 2018 to Jul 19, 2021⁷
Board memberMark A. Goldsmith Jul 18, 2018 to Jul 19, 2021¹⁸
Board memberPeter Svennilson Jul 18, 2018 to Jul 23, 2018¹⁹
Board memberRobert I. Tepper Jul 18, 2018 to Jun 10, 2019²⁰
Board memberElizabeth Trehu Sep 5, 2018 to Jul 19, 2021²¹
Board memberSteven L. Hoerter Sep 5, 2018 to Jul 23, 2021²²
General counselKaren Valentine Feb 18, 2020 to Feb 18, 2020²³

Timeline

Jul 18, 2018New chief executive Jigar Raythatha becomes CEO⁷
2008Founded Founded¹

SEC filer profile

How Constellation Pharmaceuticals (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARCONSTELLATION PHARMACEUTICALS INC²
CIK0001434418
Filer statusLarge accelerated filer²
Incorporated inDelaware²
Fiscal year endsDecember 31²
Industry code (SIC)2834 Pharmaceutical Preparations²
Business address215 First Street, Suite 200, Cambridge, MA 02142²
Phone617-714-0555²
Shares outstanding47,914,690 as of Apr 30, 2021²⁴
Public float$1.4B as of Jun 30, 2020⁵
On EDGAR sinceMay 5, 2008²
Filings314 in all: 4 (122), 8-K (39), 3 (31), SC 13G (17), SC 13G/A (15), 10-Q (9), D (7), CORRESP (6)²
All 42 form types
424B5 (4), S-8 (4), S-8 POS (4), SC 14D9/A (4), SC TO-T/A (4), UPLOAD (4), 10-K (3), 4/A (3), DEF 14A (3), DEFA14A (3), EFFECT (3), 5 (2), 8-K/A (2), CT ORDER (2), POSASR (2), S-3ASR (2), SC14D9C (2), 15-12B (1), 25-NSE (1), 3/A (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), POS AM (1), REGDEX (1), S-1 (1), S-1/A (1), S-3 (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1)
Latest filingsAnnual report (10-K) Feb 24, 2021
Quarterly report (10-Q) May 10, 2021
Proxy statement (DEF 14A) Apr 23, 2021
Latest 8-K (8-K) Jul 15, 2021

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataConstellation Pharmaceuticals (United States) on Wikidata
2
SEC EDGARConstellation Pharmaceuticals (United States) filings on SEC EDGAR
3
Company websiteConstellation Pharmaceuticals (United States) logo
4
SEC EDGARConstellation Pharmaceuticals (United States) filings on SEC EDGAR
5
SEC EDGARConstellation Pharmaceuticals (United States) 10-K for fiscal 2020
6
SEC EDGARConstellation Pharmaceuticals (United States) 10-K for fiscal 2019
7
SEC EDGARJigar Raythatha, Chief executive officer
8
SEC EDGAREmma Reeve, Chief financial officer
9
SEC EDGARJeffrey Humphrey, Chief Medical Officer
10
SEC EDGARAdrian Senderowicz, Chief Medical Officer
11
SEC EDGARKaren Valentine, Officer
12
SEC EDGARJigar Raythatha, Officer
13
SEC EDGARPatrick Trojer, Chief Scientific Officer
14
SEC EDGARScott Braunstein, Board member
15
SEC EDGARAnthony B. Evnin, Board member
16
SEC EDGARBihua Chen, Board member
17
SEC EDGARJames E. Audia, Board member
18
SEC EDGARMark A. Goldsmith, Board member
19
SEC EDGARPeter Svennilson, Board member
20
SEC EDGARRobert I. Tepper, Board member
21
SEC EDGARElizabeth Trehu, Board member
22
SEC EDGARSteven L. Hoerter, Board member
23
SEC EDGARKaren Valentine, General counsel
24
SEC EDGARConstellation Pharmaceuticals (United States) 10-Q filed May 10, 2021: shares outstanding

Overview

What it owns

Property and equipment

Real estate and locations

Investments

Leadership

Chief executive

President

Chief financial officer

Timeline

SEC filer profile

Links

Sources